(18)F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis

Rationale: The overall clinical response to FGFR inhibitor (FGFRi) is far from satisfactory in cancer patients stratified by FGFR aberration, the current biomarker in clinical practice. A novel biomarker to evaluate the therapeutic response to FGFRi in a non-invasive and dynamic manner is thus great...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yuchen, Zeng, Qinghe, Jiang, Qinghui, Peng, Xia, Gao, Jing, Wan, Haiyan, Wang, Luting, Gao, Yinglei, Zhou, Xiaoyu, Lin, Dongze, Feng, Hanyi, Liang, Sheng, Zhou, Hu, Ding, Jian, Ai, Jing, Huang, Ruimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475468/
https://www.ncbi.nlm.nih.gov/pubmed/36168616
http://dx.doi.org/10.7150/thno.74848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475468/
https://www.ncbi.nlm.nih.gov/pubmed/36168616
http://dx.doi.org/10.7150/thno.74848

Ejemplares similares